This suggests a potential interaction between the absence of RAS inhibitor therapy and elevated MMP-2 levels in patients with DCM and emphasizes the importance of RAS inhibitors in such patients, not only for their hemodynamic effects but also for their role in modulating pathological remodeling processes. This evidence concerns the gene MMP2 and familial dilated cardiomyopathy.